DE69906568T2 - Behandlung von hämorrhagischem virusfieber mit protein c - Google Patents

Behandlung von hämorrhagischem virusfieber mit protein c Download PDF

Info

Publication number
DE69906568T2
DE69906568T2 DE69906568T DE69906568T DE69906568T2 DE 69906568 T2 DE69906568 T2 DE 69906568T2 DE 69906568 T DE69906568 T DE 69906568T DE 69906568 T DE69906568 T DE 69906568T DE 69906568 T2 DE69906568 T2 DE 69906568T2
Authority
DE
Germany
Prior art keywords
protein
activated protein
fever
apc
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69906568T
Other languages
German (de)
English (en)
Other versions
DE69906568D1 (de
Inventor
Jack Charles FISHER
Betty Sau-Chi YAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardiome Pharma Corp
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE69906568D1 publication Critical patent/DE69906568D1/de
Publication of DE69906568T2 publication Critical patent/DE69906568T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
DE69906568T 1998-11-20 1999-11-15 Behandlung von hämorrhagischem virusfieber mit protein c Expired - Lifetime DE69906568T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10915398P 1998-11-20 1998-11-20
US109153P 1998-11-20
PCT/US1999/027074 WO2000030677A1 (en) 1998-11-20 1999-11-15 Method of treating viral hemorrhagic fever

Publications (2)

Publication Number Publication Date
DE69906568D1 DE69906568D1 (de) 2003-05-08
DE69906568T2 true DE69906568T2 (de) 2004-02-12

Family

ID=22326085

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69906568T Expired - Lifetime DE69906568T2 (de) 1998-11-20 1999-11-15 Behandlung von hämorrhagischem virusfieber mit protein c

Country Status (12)

Country Link
US (2) US6270764B1 (enExample)
EP (1) EP1131091B1 (enExample)
JP (1) JP2002530353A (enExample)
CN (1) CN1326356A (enExample)
AT (1) ATE235915T1 (enExample)
AU (1) AU2149800A (enExample)
BR (1) BR9915460A (enExample)
CA (1) CA2351470A1 (enExample)
DE (1) DE69906568T2 (enExample)
ES (1) ES2195655T3 (enExample)
IL (1) IL142220A0 (enExample)
WO (1) WO2000030677A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000030677A1 (en) * 1998-11-20 2000-06-02 Eli Lilly And Company Method of treating viral hemorrhagic fever
WO2002024215A2 (en) * 2000-09-18 2002-03-28 Eli Lilly And Company Method for using activated protein c for the treatment of coagulation-associated disorders
BR0213293A (pt) 2001-10-15 2004-12-21 Chiron Corp Uso de tfpi ou de um análogo de tfpi no tratamento de septicemia
US7132398B2 (en) 2003-05-06 2006-11-07 Dendreon Corporation Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor
MXPA06010587A (es) * 2004-03-17 2007-03-29 Chiron Corp Tratamiento de neumonia severa adquirida en comunidad por administracion del inhibidor de la via del factor tisular (tfpi).
WO2007092607A2 (en) * 2006-02-09 2007-08-16 Genetech, Inc. Treatment of hemorrhagic viral infections using a tissue factor inhibitor
RU2379034C1 (ru) * 2008-11-17 2010-01-20 Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева" Способ лечения геморрагической лихорадки с почечным синдромом
US20200093853A1 (en) * 2016-12-08 2020-03-26 Cellphire, Inc. Compositions and methods for treatment of loss of fluids leading to hypotension and/or hypovolemia
EP3887404A4 (en) 2018-11-30 2022-11-02 Cellphire, Inc. SLIDES LOADED WITH ANTI-CANCER AGENTS
US11767511B2 (en) 2018-11-30 2023-09-26 Cellphire, Inc. Platelets as delivery agents
CA3138529C (en) 2019-05-03 2025-10-07 Cellphire, Inc. MATERIALS AND PROCESSES FOR THE PRODUCTION OF BLOOD PRODUCTS
WO2021034719A1 (en) 2019-08-16 2021-02-25 Cellphire, Inc. Thrombosomes as an antiplatelet agent reversal agent
CA3170196A1 (en) 2020-02-04 2021-08-12 Cellphire, Inc. Anti-fibrinolytic loaded platelets
TW202245814A (zh) 2021-02-17 2022-12-01 美商賽菲爾公司 用於治療抗血小板誘導的凝血病之凍乾血小板衍生物組成物
US12702682B2 (en) 2021-11-04 2026-08-11 Cellphire, Inc. Platelet derivative compositions, and methods of making and using such compositions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5550036A (en) 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
US4992373A (en) 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5506134A (en) * 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
AT402262B (de) 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
ZA983497B (en) * 1997-04-28 1999-10-25 Lilly Co Eli Activated protein c formulations.
WO2000030677A1 (en) * 1998-11-20 2000-06-02 Eli Lilly And Company Method of treating viral hemorrhagic fever
JP2002542832A (ja) * 1999-04-30 2002-12-17 イーライ・リリー・アンド・カンパニー プロテインｃ誘導体

Also Published As

Publication number Publication date
ES2195655T3 (es) 2003-12-01
ATE235915T1 (de) 2003-04-15
US6767539B2 (en) 2004-07-27
DE69906568D1 (de) 2003-05-08
US20010028880A1 (en) 2001-10-11
CN1326356A (zh) 2001-12-12
CA2351470A1 (en) 2000-06-02
US6270764B1 (en) 2001-08-07
EP1131091A1 (en) 2001-09-12
WO2000030677A1 (en) 2000-06-02
IL142220A0 (en) 2002-03-10
AU2149800A (en) 2000-06-13
JP2002530353A (ja) 2002-09-17
BR9915460A (pt) 2001-07-17
EP1131091B1 (en) 2003-04-02

Similar Documents

Publication Publication Date Title
DE69828462T2 (de) Verwendung von APC, in Kombination mit Blutplättchenaggregationshemmer, zur Behandlung thrombothischer Störungen
DE69828330T2 (de) Aktiviertes Protein C Formulierungen
DE69829721T2 (de) Verwendung von aktiviertem Protein-C zur Behandlung überschiessender Blutgerinnung bei Sepsis
DE3240174C2 (enExample)
DE3855096T2 (de) Hemmung von arteriellem thrombotischen Verschluss oder von Thrombo-Embolismus
DE69030189T2 (de) Hemmung des wachstums von tumoren durch blockade des protein-c-systems
DE69006851T2 (de) Blutgerinnungshemmende zusammensetzungen aus faktor xa.
DE3617753C2 (enExample)
AT402367B (de) Pharmazeutische zubereitung auf basis von lys-plasminogen
DE4411143C2 (de) Thrombosemittel
US6767539B2 (en) Method of treating viral hemorrhagic fever
DE69429816T2 (de) C1-Esterasehemmer zur Verringerung von Myokardschäden bei akutem Herzinfarkt
DE3433329A1 (de) Pharmazeutische zusammensetzung zur behandlung der stadien akuter niereninsuffizienz
DE69232596T2 (de) Inhibitor von nebenwirkungen zur krebstherapy
AT397615B (de) Arzneimittel enthaltend protein c
DE69905489T2 (de) Protein c zur behandlung von sichelzellanämie und thalassämie
DE60108076T2 (de) Protein c derivate
DE69930419T2 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
DE69916493T2 (de) Verwendung von protein c zur behandlung von thrombozytopenischer purpura und hämolytisches urämisches syndrom
DE69833727T2 (de) Verfahren zur Behandlung der Gefässerkrankungen mit aktiviertem Protein C
DE60004185T2 (de) Supar stimulierende aktivität auf die tcupa vermittelte fibrinolyse und verschiedene verwendungen davon
WO2024012853A1 (de) Arzneimittel zur förderung der hämostase
WO2003054015A2 (de) Verwendung von koagulationsaktivem antithrombin iii zur therapie von angiogenese-abhängigen erkrankungen
EP0400617A2 (de) Oxydantien als systemisches (parenterales) Arzneimittel
DE20221790U1 (de) Koagulationsaktives Antithrombin III und dessen Verwendung zur Prophylaxe und Therapie von Angiogenese-abhängigen Erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CARDIOME PHARMA CORP., VANCOUVER, CA

8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN